NCT04925648 (PICASSO) is a Phase 2 clinical trial of Dasatinib in Metastatic Prostate Cancer, sponsored by St Vincent's Hospital, Sydney.

Who is sponsoring NCT04925648?

NCT04925648 is sponsored by St Vincent's Hospital, Sydney.

What drugs are being tested in NCT04925648?

Interventions in NCT04925648: Dasatinib, Darolutamide.

What condition does NCT04925648 study?

NCT04925648 studies Metastatic Prostate Cancer.

Is NCT04925648 still recruiting?

NCT04925648 is currently recruiting now. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT04925648: PICASSO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

Recruiting now Phase 2 Last updated 15 May 2025

What this trial tests

Phase 2 trial testing Dasatinib in Metastatic Prostate Cancer in 22 participants. Currently enrolling.

Timeline

18 October 2021

Primary endpoint
1 September 2025

1 December 2025

Quick facts

Lead sponsor	St Vincent's Hospital, Sydney
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	18 October 2021
Primary completion	1 September 2025
Estimated completion	1 December 2025
Sites	2 locations across Australia

Drugs / interventions tested

Dasatinib (dasatinib) — full drug profile →
Darolutamide (darolutamide) — full drug profile →

Conditions studied

Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

St Vincent's Hospital, Sydney

Who can join

18 and older, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study's purpose is to understand the appearance of your prostate-specific membrane antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib alone or in combination with anti-testosterone drug call darolutamide. Who is it for? You may be eligible to join this study if you have metastatic prostate cancer and had a recent PSMA scan showing low PSMA uptake Study Details: Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide 600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days. Participants will be followed up on day 7 of treatment and 30 days after treatment. It is hoped that this research will provide insight into the mechanism of PSMA expression in advanced prostate cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer.
Miller KJ, Asim M. · · 2022 · cited 8× · PMID 35326402 · DOI 10.3390/cells11060952
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications.
Singh N, Heemers HV. · · 2023 · PMID 37279256 · DOI 10.1530/erc-23-0011

Verify or expand the search:

Other trials of Dasatinib

Trials testing the same drug.

NCT07269470 — Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly · Phase 2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting
NCT07493408 — Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of · Phase 2 · not yet recruiting
NCT07144293 — Improving Physical Ability and Cellular Senescence Elimination in HIV · Phase 2 · active not recruiting
NCT05751044 — HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps · Phase 1, PHASE2 · recruiting

Other recruiting trials for Metastatic Prostate Cancer

Currently open trials in the same condition.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting

Other St Vincent's Hospital, Sydney trials

Trials by the same sponsor.

NCT07203391 — Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis · Phase 1 · recruiting
NCT05889728 — Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer · Phase 2 · unknown
NCT05613842 — Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) · Phase 2 · completed
NCT05187884 — Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma · Phase 2 · active not recruiting
NCT03714048 — Blood Management During ECMO for Cardiac Support · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04925648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St Vincent's Hospital, Sydney
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04925648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing